MBRX — Moleculin Biotech, Inc.
$6.50+10.36%
Last close: · regular session
Last 60 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for MBRX in the TickerWise workspace.
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company dedicated to advancing therapeutic candidates designed to combat highly aggressive cancers and viral infections. Their primary investigational drug, Annamycin, is currently undergoing Phase 1/2 clinical trials. These trials aim to assess its efficacy against acute myeloid leukemia (AML) that has relapsed or is resistant to prior therapies, as well as malignancies that have spread to the lungs. WP1066, a prominent immune/transcription modulator for the company, is presently in Phase I studies, targeting both adult and pediatric brain tumors, pancreatic cancer, and other types of aggressive malignancies. Further, the firm is developing WP1220, an analog of WP1066, intended for topical application in treating cutaneous T-cell lymphoma. Another compound, WP1122, is under development for glioblastoma multiforme and COVID-19. Moleculin Biotech has established collaboration agreements and partnerships with organizations such as MD Anderson, Animal Life Sciences, LLC, and WPD Pharmaceuticals Sp z.o.o. The company was founded in 2015 and maintains its principal offices in Houston, Texas.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ Capital Market
- Employees: 17
- Website: https://www.moleculin.com
Latest SEC filings for MBRX
Latest MBRX news
- Moleculin announces 1-for-20 reverse stock split, shares slide Read article
- Moleculin Biotech to Participate in Advances in Oncology Panel at the 2026 Maxim Growth Summit Read article
- Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine Read article
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.